$ERNA News

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy

Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Ernexa Therapeutics Advances ERNA-101 Toward IND Filing In Q3 2026; Targeting Phase 1 Cancer Trial Initiation In Q4 2026

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

Ernexa Therapeutics Announces Progress In Development Of ERNA-101; Hits Multiple Milestones Ahead Of Planned IND Submission In Q3 2026 And First‑In‑Human Study Initiation

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

Ernexa Stock Is Jumping Today: What's Going On?

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

Brookline Capital Initiates Coverage On Ernexa Therapeutics with Buy Rating, Announces Price Target of $30

Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data

Ernexa Therapeutics Announces Its Preclinical Data From Its ERNA-101 Candidate Demonstrates 100% Long-Term Survival In Syngeneic Ovarian Cancer Models